Browsing by Author "Pinero, Federico"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Assessing the impact of COVID-19 on liver cancer management (CERO-19)
    (2021) Munoz-Martinez, Sergio; Sapena, Victor; Forner, Alejandro; Nault, Jean-Charles; Sapisochin, Gonzalo; Rimassa, Lorenza; Sangro, Bruno; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Holowko, Waclaw; El Kassas, Mohamed; Mocan, Tudor; Bouattour, Mohamed; Merle, Philippe; Hoogwater, Frederik J. H.; Alqahtani, Saleh A.; Reeves, Helen L.; Pinato, David J.; Giorgakis, Emmanouil; Meyer, Tim; Villadsen, Gerda Elisabeth; Wege, Henning; Salati, Massimiliano; Minguez, Beatriz; Di Costanzo, Giovan Giuseppe; Roderburg, Christoph; Tacke, Frank; Varela, Maria; Galle, Peter R.; Alvares-da-Silva, Mario Reis; Trojan, Joerg; Bridgewater, John; Cabibbo, Giuseppe; Toso, Christian; Lachenmayer, Anja; Casadei-Gardini, Andrea; Toyoda, Hidenori; Luedde, Tom; Villani, Rosanna; Matilla Pena, Ana Maria; Guedes Leal, Cassia Regina; Ronzoni, Monica; Delgado, Manuel; Perello, Christie; Pascual, Sonia; Luis Lledo, Jose; Argemi, Josepmaria; Basu, Bristi; da Fonseca, Leonardo; Acevedo, Juan; Siebenhuener, Alexander R.; Braconi, Chiara; Meyers, Brandon M.; Granito, Alessandro; Sala, Margarita; Rodriguez-Lope, Carlos; Blaise, Lorraine; Romero-Gomez, Manuel; Pinero, Federico; Gomez, Dhanny; Mello, Vivianne; Pinheiro Alves, Rogerio Camargo; Franca, Alex; Branco, Fernanda; Brandi, Giovanni; Pereira, Gustavo; Coll, Susanna; Guarino, Maria; Benitez, Carlos; Margarita Anders, Maria; Bandi, Juan C.; Vergara, Mercedes; Calvo, Mariona; Peck-Radosavljevic, Markus; Garcia-Juarez, Ignacio; Cardinale, Vincenzo; Lozano, Mar; Gambato, Martina; Okolicsanyi, Stefano; Morales-Arraez, Dalia; Elvevi, Alessandra; Munoz, Alberto E.; Lue, Alberto; Iavarone, Massimo; Reig, Maria
    Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.
  • No Thumbnail Available
    Item
    Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America
    (2023) Mendizabal, Manuel; Thompson, Marcos; Gonzalez-Ballerga, Esteban; Anders, Margarita; Castro-Narro, Graciela E.; Pessoa, Mario G.; Cheinquer, Hugo; Mezzano, Gabriel; Palazzo, Ana; Ridruejo, Ezequiel; Descalzi, Valeria; Velarde-Ruiz Velasco, Jose A.; Marciano, Sebastian; Munoz, Linda; Schinoni, Maria, I; Poniachik, Jaime; Perazzo, Rosalia; Cerda, Eira; Fuster, Francisco; Varon, Adriana; Ruiz Garcia, Sandro; Soza, Alejandro; Cabrera, Cecilia; Gomez-Aldana, Andres J.; de Maria Beltran, Flor; Gerona, Solange; Cocozzella, Daniel; Bessone, Fernando; Hernandez, Nelia; Alonso, Cristina; Ferreiro, Melina; Antinucci, Florencia; Torre, Aldo; Moutinho, Bruna D.; Coelho Borges, Silvia; Gomez, Fernando; Dolores Murga, Maria; Pinero, Federico; Sotera, Gisela F.; Ocampo, Jhonier A.; Cortes Mollinedo, Valeria A.; Simian, Daniela; Silva, Marcelo O.
    To achieve WHO's goal of eliminating hepatitis C virus (HCV), innovative strategies must be designed to diagnose and treat more patients. Therefore, we aimed to describe an implementation strategy to identify patients with HCV who were lost to follow-up (LTFU) and offer them re-linkage to HCV care. We conducted an implementation study utilizing a strategy to contact patients with HCV who were not under regular follow-up in 13 countries from Latin America. Patients with HCV were identified by the international classification of diseases (ICD-9/10) or equivalent. Medical records were then reviewed to confirm the diagnosis of chronic HCV infection defined by anti-HCV+ and detectable HCV-RNA. Identified patients who were not under follow-up by a liver specialist were contacted by telephone or email, and offered a medical reevaluation. A total of 10,364 patients were classified to have HCV. After reviewing their medical charts, 1349 (13%) had undetectable HCV-RNA or were wrongly coded. Overall, 9015 (86.9%) individuals were identified with chronic HCV infection. A total of 5096 (56.5%) patients were under routine HCV care and 3919 (43.5%) had been LTFU. We were able to contact 1617 (41.3%) of the 3919 patients who were LTFU at the primary medical institution, of which 427 (26.4%) were cured at a different institutions or were dead. Of the remaining patients, 906 (76.1%) were candidates for retrieval. In our cohort, about one out of four patients with chronic HCV who were LTFU were candidates to receive treatment. This strategy has the potential to be effective, accessible and significantly impacts on the HCV care cascade.
  • No Thumbnail Available
    Item
    Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region
    (2021) Pinero, Federico; Anders, Margarita; Boin, Ilka F.; Chagas, Aline; Quinonez, Emilio; Marciano, Sebastian; Vilatoba, Mario; Santos, Luisa; Hoyos Duque, Sergio; Lima, Agnaldo Soares; Menendez, Josemaria; Padilla, Martin; Poniachik, Jaime; Zapata, Rodrigo; Soza, Alejandro; Maraschio, Martin; Chong Menendez, Ricardo; Munoz, Linda; Arufe, Diego; Figueroa, Rodrigo; de Ataide, Elaine Cristina; Maccali, Claudia; Vergara Sandoval, Rodrigo; Bermudez, Carla; Podesta, Luis G.; McCormack, Lucas; Varon, Adriana; Gadano, Adrian; Mattera, Juan; Villamil, Federico; Rubinstein, Fernando; Carrilho, Flair; Silva, Marcelo
    This study aimed to compare liver transplantation (LT) outcomes and evaluate the potential rise in numbers of LT candidates with hepatocellular carcinoma (HCC) of different allocation policies in a high waitlist mortality region. Three policies were applied in two Latin American cohorts (1085 HCC transplanted patients and 917 listed patients for HCC): (i) Milan criteria with expansion according to UCSF downstaging (UCSF-DS), (ii) the AFP score, and (iii) restrictive policy or Double Eligibility Criteria (DEC; within Milan + AFP score <= 2). Increase in HCC patient numbers was evaluated in an Argentinian prospective validation set (INCUCAI; NCT03775863). Expansion criteria in policy A showed that UCSF-DS [28.4% (CI 12.8-56.2)] or "all-comers" [32.9% (CI 11.9-71.3)] had higher 5-year recurrence rates compared to Milan, with 10.9% increase in HCC patients for LT. The policy B showed lower recurrence rates for AFP scores <= 2 points, even expanding beyond Milan criteria, with a 3.3% increase. Patients within DEC had lower 5-year recurrence rates compared with those beyond DEC [13.3% (CI 10.1-17.3) vs 24.2% (CI 17.4-33.1; P = 0.0006], without significant HCC expansion. In conclusion, although the application of a stricter policy may optimize the selection process, this restrictive policy may lead to ethical concerns in organ allocation (NCT03775863).
  • Thumbnail Image
    Item
    Results of liver transplantation for hepatocellular carcinoma in a multicenter latin American cohort study
    (2018) Pinero, Federico; Costa, Paulo; Boteon, Yuri L.; Hoyos Duque, Sergio; Marciano, Sebastian; Anders, Margarita; Varón, Adriana; Zerega, Alina; Poniachik, Jaime; Soza, Alejandro; Padilla Machaca, Martín; Menéndez, Josemaría; Zapata, Rodrigo; Vilatoba, Mario; Muñoz, Linda; Maraschio, Martín; Fauda, Martín; McCormack, Lucas; Gadano, Adrian; Boin, Ilka SF; Parente García, Jose H.; Silva, Marcelo